The CpG oligonucleotide TLR9 ODN 1826 agonist has been shown to effectively augment the therapeutic potential of checkpoint blockade through locally delivered ODN 1826 and systemic CTLA4 or PD-1 blockade antibody in the B16 melanoma mouse model.37 This evidence concerns the gene TLR9 and melanoma.